0001744333-23-000001.txt : 20231201 0001744333-23-000001.hdr.sgml : 20231201 20231201165137 ACCESSION NUMBER: 0001744333-23-000001 CONFORMED SUBMISSION TYPE: D PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: 06b FILED AS OF DATE: 20231201 DATE AS OF CHANGE: 20231201 EFFECTIVENESS DATE: 20231201 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ELIXIRGEN THERAPEUTICS, INC. CENTRAL INDEX KEY: 0001744333 IRS NUMBER: 830534578 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: D SEC ACT: 1933 Act SEC FILE NUMBER: 021-498657 FILM NUMBER: 231460259 BUSINESS ADDRESS: STREET 1: 855 N. WOLFE ST. STREET 2: SUITE 624 CITY: BALTIMORE STATE: MD ZIP: 21205 BUSINESS PHONE: 443-451-5300 MAIL ADDRESS: STREET 1: 855 N. WOLFE ST. STREET 2: SUITE 624 CITY: BALTIMORE STATE: MD ZIP: 21205 D 1 primary_doc.xml X0708 D LIVE 0001744333 ELIXIRGEN THERAPEUTICS, INC. 855 N. WOLFE ST. SUITE 624 BALTIMORE MD MARYLAND 21205 443-451-5300 DELAWARE None None Corporation true 2018 Akihiro C Ko 855 N. Wolfe Street, Suite 624 Baltimore MD MARYLAND 21205 Executive Officer Director Hiroaki Kobayashi 855 N. Wolfe Street, Suite 624 Baltimore MD MARYLAND 21205 Director Minoru S.H. Ko 855 N. Wolfe Street, Suite 624 Baltimore MD MARYLAND 21205 Director Thomas K. White 855 N. Wolfe Street, Suite 624 Baltimore MD MARYLAND 21205 Director Shauna Callahan 855 N. Wolfe Street, Suite 624 Baltimore MD MARYLAND 21205 Director Jeffrey Cleland 855 N. Wolfe Street, Suite 624 Baltimore MD MARYLAND 21205 Director Biotechnology Decline to Disclose 06b false 2023-11-09 false true false 0 6999988 6999988 0 This pertains to the issuance of Series A-3 Preferred Units, including the conversion of convertible securities false 1 0 0 0 false ELIXIRGEN THERAPEUTICS, INC. Akihiro Ko Akihiro Ko CEO 2023-11-09